$0.27
6.00%
Nasdaq, Apr 21, 08:18 pm CET
ISIN
US75120L1008
Symbol
RLYB

Rallybio Corp Stock price

$0.25
-0.39 61.07% 1M
-0.84 77.06% 6M
-0.71 73.96% YTD
-1.51 85.80% 1Y
-8.62 97.18% 3Y
-13.85 98.23% 5Y
-13.85 98.23% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.00 0.71%
ISIN
US75120L1008
Symbol
RLYB
Sector
Industry

Key metrics

Market capitalization $10.40m
Enterprise Value $-54.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.12
EV/Sales (TTM) EV/Sales -85.88
P/S ratio (TTM) P/S ratio 16.25
P/B ratio (TTM) P/B ratio 0.17
Revenue (TTM) Revenue $640.00k
EBIT (operating result TTM) EBIT $-60.50m
Free Cash Flow (TTM) Free Cash Flow $-49.28m
Cash position $65.51m
EPS (TTM) EPS $-1.34
P/E forward negative
Short interest 1.16%
Show more

Is Rallybio Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Rallybio Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Rallybio Corp forecast:

2x Buy
40%
3x Hold
60%

Analyst Opinions

5 Analysts have issued a Rallybio Corp forecast:

Buy
40%
Hold
60%

Financial data from Rallybio Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.64 0.64
-
100%
- Direct Costs 0.13 0.13
13% 13%
20%
0.51 0.51
440% 440%
80%
- Selling and Administrative Expenses 19 19
23% 23%
3,045%
- Research and Development Expense 41 41
22% 22%
6,466%
-60 -60
23% 23%
-9,433%
- Depreciation and Amortization 0.13 0.13
13% 13%
20%
EBIT (Operating Income) EBIT -60 -60
23% 23%
-9,453%
Net Profit -58 -58
23% 23%
-9,028%

In millions USD.

Don't miss a Thing! We will send you all news about Rallybio Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rallybio Corp Stock News

Neutral
Business Wire
13 days ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The Company's decision to discontinue RLYB...
Neutral
Business Wire
about one month ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on recent company developments. “We are pleased with our stro...
Neutral
Business Wire
about 2 months ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will present a corporate overview at the TD Cowen 45th Annual Health Care Conference on Tuesday, Marc...
More Rallybio Corp News

Company Profile

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focuses in the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Head office United States
CEO Stephen Uden
Employees 25
Founded 2018
Website www.rallybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today